At its meeting on 12 September 2022 the Transparency Council adopted position No. 88/2022 on on the legitimacy of granting consent for reimbursement of the medicinal product Vivitrol (extended-release naltrexone) for the indication: mental and behavioural disorders due to alcohol use (F10), including dependence syndrome.
Publication in Public Information Bulletin (BIP)